# Immutrin

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immutrin

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.immutrin.com/
- Total disclosed funding: $173M
- Latest round: Series A (Nov 3, 2026)
- Investors on record: 9

## About

Based in the UK, and founded in 2019 co-founded by Cambridge Innovation Capital, academic founders Professor Sir Mark Pepys FRS, Nobel Laureate Sir Gregory Winter FRS and Professor Daniel Christ, Immutrin Ltd specializes in developing innovative antibody therapies aimed at treating ATTR cardiomyopathy, a severe form of amyloidosis, with a focus on improving patient outcomes. Immutrin Ltd, headquartered in Cambridge, UK, is a biotechnology company dedicated to addressing the challenges of ATTR cardiomyopathy through its proprietary antibody therapy. The company has secured substantial funding, raising GBP 65 million in its SERIES A round, led by Frazier Life Sciences, with contributions from investors including Cambridge Enterprise and Cambridge Innovation Capital. This funding supports its ongoing research initiatives and product development. Mihriban Tuna is the current CEO of this company. Immutrin’s core product offering centers around its proprietary antibody therapy developed for the treatment of ATTR cardiomyopathy, a severe and progressive form of amyloidosis. The therapy operates through a unique mechanism designed to selectively and exclusively remove established amyloid fibrils, addressing a critical need in the management of this condition. This innovative solution aims to improve patient outcomes by reversing the adverse effects of amyloidosis on cardiovascular health. Immutrin targets healthcare providers and hospitals specializing in cardiology and hematology, focusing on markets in North America, Europe, and Asia, where the prevalence of amyloidosis conditions warrants advanced therapeutic options. Immutrin generates revenue primarily through partnerships and collaborations with healthcare institutions and biopharmaceutical companies engaged in the treatment of amyloidosis. The business model is structured around licensing agreements and joint ventures that facilitate the development and distribution of its flagship antibody therapy. Revenue streams may include milestone payments, royalties from product sales, and potential profit-sharing arrangements. Given the specialized nature of the therapeutic market, transactions typically involve direct engagement with healthcare providers, ensuring that the therapy reaches patients who benefit from its unique attributes in treating ATTR cardiomyopathy. Immutrin Ltd intends to expand its product portfolio by developing additional therapies targeting other forms of amyloidosis, with plans for product launches in the next 12 to 24 months. The company is also focusing on entering new geographic markets, particularly in Asia and North America, to broaden access to its therapies by the end of 2024. Recent funding from the SERIES A round will be utilized to support these initiatives, enhancing research and development capabilities and fostering strategic partnerships to accelerate market entry.

## Funding rounds

- Series A, Nov 3, 2026, $86M — Frazier Life Sciences, Cambridge Enterprise Ventures, Cambridge Innovation Capital, F-Prime, Qiming, SR One
- Series A, Mar 24, 2026, $87M — SR One, Qiming Venture Partners, Cambridge Enterprise, F-Prime Capital, Cambridge Innovation Capital, Frazier Life Sciences

## Investors

- SR One (https://capitalatlas.ai/funds/sr-one) — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A
- Cambridge Enterprise — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Series A
- Frazier Life Sciences — Series A
- Cambridge Enterprise Ventures (https://capitalatlas.ai/funds/cambridge-enterprise-ventures) — Series A
- F-Prime — Series A
- Qiming — Series A